These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1725922)

  • 21. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.
    Donnelly JJ; Deck RR; Liu MA
    J Immunol; 1990 Nov; 145(9):3071-9. PubMed ID: 2120344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis.
    Høiby EA; Bjune G; Frøholm LO; Eng J; Halstensen A; Rosenqvist E; Rønnild E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):107-21; discussion 121-3. PubMed ID: 1812424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent trends in the developments of bacterial vaccines.
    Lindberg AA; Pillai S
    Dev Biol Stand; 1996; 87():59-71. PubMed ID: 8854003
    [No Abstract]   [Full Text] [Related]  

  • 24. A critical contribution of both CD28 and ICOS in the adjuvant activity of Neisseria meningitidis H44/76 LPS and lpxL1 LPS.
    van Berkel ME; Schrijver EH; van Mourik A; Tesselaar K; van der Ley P; Steeghs L; Oosterwegel MA
    Vaccine; 2007 Jun; 25(24):4681-8. PubMed ID: 17499399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meningococcal disease in São Paulo, Brazil.
    Costa W; Sacchi CT; Ramos S; Milagres L; Prigenzi LS
    NIPH Ann; 1991 Dec; 14(2):215-6; discussion 216-8, 222-4. PubMed ID: 1812434
    [No Abstract]   [Full Text] [Related]  

  • 26. [Anti-meningococcal polysaccharide vaccines].
    Gómez JA; Ferreirós CM; Criado MT
    Enferm Infecc Microbiol Clin; 1997; 15(7):347-8. PubMed ID: 9410045
    [No Abstract]   [Full Text] [Related]  

  • 27. Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines.
    Andersen SR; Bjune G; Lyngby J; Bryn K; Jantzen E
    Microb Pathog; 1995 Sep; 19(3):159-68. PubMed ID: 8559044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.
    Sierra GV; Campa HC; Varcacel NM; Garcia IL; Izquierdo PL; Sotolongo PF; Casanueva GV; Rico CO; Rodriguez CR; Terry MH
    NIPH Ann; 1991 Dec; 14(2):195-207; discussion 208-10. PubMed ID: 1812432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum opsonins to serogroup B meningococci after disease and vaccination.
    Halstensen A; Lehmann AK; Guttormsen HK; Vollset SE; Bjune G; Naess A
    NIPH Ann; 1991 Dec; 14(2):157-65; discussion 166-7. PubMed ID: 1812430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal administration of a detoxified endotoxin vaccine protects mice against heterologous Gram-negative bacterial pneumonia.
    Chen WH; Kang TJ; Bhattacharjee AK; Cross AS
    Innate Immun; 2008 Oct; 14(5):269-78. PubMed ID: 18809651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic antigens of Haemophilus influenzae as vaccine components.
    Murphy TF; Campagnari AA; Nelson MB; Apicella MA
    Pediatr Infect Dis J; 1989 Jan; 8(1 Suppl):S66-8. PubMed ID: 2648296
    [No Abstract]   [Full Text] [Related]  

  • 33. Serum antibodies to capsular polysaccharide vaccine of group A and C Neisseria meningitidis in military recruits in Italy.
    Occhionero M; Usai G; Di Martino M; Le Moli S; Stroffolini T; Mastrantonio P
    Allergol Immunopathol (Madr); 1991; 19(1):39-41. PubMed ID: 1950941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current trends in the development of vaccines].
    Zwisler O
    Zentralbl Bakteriol Mikrobiol Hyg B; 1985 Feb; 180(2-3):165-74. PubMed ID: 2859720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meningococcal vaccines.
    Bethell D; Pollard AJ
    Expert Rev Vaccines; 2002 Jun; 1(1):75-84. PubMed ID: 12908514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The status of vaccines to meningococcal and gonococcal disease.
    Gotschlich EC
    Ann Inst Pasteur Microbiol (1985); 1985; 136B(3):341-55. PubMed ID: 2870677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine development targeting lipopolysaccharide structure modification.
    Zhao Y; Arce-Gorvel V; Conde-Álvarez R; Moriyon I; Gorvel JP
    Microbes Infect; 2018; 20(9-10):455-460. PubMed ID: 29233768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on the potential for successful development of outer membrane protein vaccines.
    Gilleland HE; Matthews-Greer JM
    Eur J Clin Microbiol; 1987 Jun; 6(3):231-3. PubMed ID: 3305003
    [No Abstract]   [Full Text] [Related]  

  • 39. [Glycopolymers of microorganisms: achievements and future research (review)].
    Varbanets LD
    Prikl Biokhim Mikrobiol; 2014; 50(6):547-60. PubMed ID: 25726663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibacterials: A sweet vaccine.
    Bundle D
    Nat Chem; 2016 Mar; 8(3):201-2. PubMed ID: 26892546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.